Article
TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
The Journal of biological chemistry - 17 Nov 1995
Lorenz M C, Heitman J
Abstract excerpt
The antifungal, immunosuppressive compound rapamycin arrests the cell cycle in G1 in both yeast cells and T-lymphocytes. Previous genetic studies in yeast identified mutations in three genes, FPR1 (FKBP12), TOR1, and TOR2, which confer rapamycin resistance, and genetic findings implicated the TOR proteins as direct targets of FKBP12-rapamycin. Consistent with this model, we find that modulating TOR1 and TOR2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
